Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer

This study has been terminated.
Information provided by:
PhytoCeutica Identifier:
First received: May 10, 2002
Last updated: June 23, 2005
Last verified: September 2004
The triple combination chemotherapy of irinotecan, 5-fluorouracil and leucovorin (CPT-11/5-FU/LV or Saltz regimen) is the treatment of choice for patients with advanced colorectal cancer. Severe diarrhea, unfortunately, is a side effect of such treatment. Preclinical studies have indicated that the botanical drug PHY906 can reduce such diarrhea without compromising the effectiveness of the chemotherapy. The primary purpose of this clinical study is to evaluate the safety, tolerability and minimum effective dose of PHY906 when administered in conjunction with the Saltz regimen.

Condition Intervention Phase
Colorectal Neoplasms
Drug: PHY906
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase I/IIA, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover, Dose Escalation, Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer

Resource links provided by NLM:

Further study details as provided by PhytoCeutica:

Estimated Enrollment: 30
Study Start Date: February 2002
Estimated Study Completion Date: March 2003
Detailed Description:
CPT-11/5-FU/LV is an active combination agent in the treatment of colorectal cancer, but one of its dose-limiting toxicities is diarrhea. PHY906 has been shown to reduce the severity of CPT-11–induced toxicity without compromising antitumor efficacy in in vivo animal models. Additionally, there has been a long historical experience in the Far East demonstrating safety of PHY906 in humans. Thus, we are conducting this double-blind, placebo-controlled study to evaluate the safety and tolerability of PHY906. This dose escalation study will also examine the effect of PHY906 (1.2, 2.4, and 3.6 g/day) on the pharmacokinetics of CPT-11 and 5-FU after concomitant administration with CPT-11, 5-FU, and LV, and on the severity of CPT-11–induced toxicities such as diarrhea.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Patients must:

  • be between 18 and 75 years of age, inclusive, at the time of enrollment.
  • have advanced colorectal carcinoma, which may be either measurable or non-measurable.
  • not have received either CPT-11, FU, or other cytotoxic chemotherapy agents in any setting (including adjuvant) within 1 year prior to screening.
  • have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • use an effective contraceptive method if the patients are of reproductive potential while enrolled in the study, since the potential effects of the herbs on a developing fetus are unknown.
  • have an estimated life expectancy of at least 20 weeks.
  • provide written informed consent.
  • have adequate organ function as indicated by the following laboratory values; these laboratory values must be obtained within 14 days prior to study enrollment:
  • Bone marrow reserve: absolute granulocyte count (AGC) more than or equal to 1.5 X 10(to the power of 9)/L, platelet count more than or equal to 100 X 10 (to the power of 9)/L, and hemoglobin level more than or equal to 9 g/dL.
  • Hepatic function: serum total bilirubin concentration no greater than 1.5 mg/dL, aspartate transaminase (AST or serum glutamic-oxaloacetic transaminase [SGOT]), and alanine transaminase (ALT or serum glutamic-pyruvic transaminase [SGPT]) levels no greater than grade 2 toxicity as determined from the NCI-CTC version 2.0.
  • Renal function: serum creatinine level no greater than grade 2 toxicity as determined from the CTC version 2.0.

Exclusion Criteria

Patients who have or are:

  • Gilbert syndrome (familial, non-hemolytic, acholuric jaundice).
  • patients with enterostomies.
  • untreated brain metastases or deteriorating neurological function after the completion of cranial irradiation.
  • a woman who is currently pregnant and/or breast-feeding.
  • active infections or any serious systemic disorder that, in the opinion of the principal investigator, are incompatible with the study product and/or procedures.
  • used an investigational agent within 4 weeks of study entry.
  • a known hypersensitivity to the study medication, its excipients, its analogs, or any of the component herbs.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00036517

United States, Connecticut
VA CT Cancer Center
West Haven, Connecticut, United States, 06516
United States, New York
Weill Cornell Medical Center
New York, New York, United States, 10021
United States, South Carolina
Cancer Centers of the Carolinas
Greenville, South Carolina, United States, 29615
Sponsors and Collaborators
Study Director: Wayne D Brenckman, Jr., MD Inveresk Research
  More Information Identifier: NCT00036517     History of Changes
Other Study ID Numbers: PHY906-2000-1
Study First Received: May 10, 2002
Last Updated: June 23, 2005

Keywords provided by PhytoCeutica:
Stage III and Stage IV colorectal cancer
Saltz regimen
side effect
botanical drug
herbal medicine
chinese herbal medicine
traditional chinese medicine
oral dose
oral administration
concomitant use

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Signs and Symptoms, Digestive
Signs and Symptoms processed this record on April 26, 2017